物理性质
- 熔点>173°C (分解)
- 沸点768.3 °C at 760 mmHg
- 闪点418.4 °C
- PSA:183.21
- LogP:-1.7926
- 溶解性水: Soluble50mg/mL
- 敏感性水溶液相对稳定;酸性溶液相对不稳定。
- 外观形态白色至淡黄色粉末
- 储存条件2-8°C
- 产品应用替卡西林钠 (4697-14-7)临床用于治疗败血症,泌尿道感染,呼吸道感染和胆道感染,也用于白血病及恶性肿瘤患者的继发感染,对伤寒也有效.本品为半合成青霉素,对绿脓杆菌有高效,临床治疗绿脓杆菌感染有效率为90%左右.对耐药性绿脓杆菌产生的β-内酰胺酶稳定,但易受大肠杆菌,奇异变形杆菌以及个别绿脓杆菌菌株产生的β-内酰胺酶所破坏.和庆大霉素,多黏菌素合用对绿脓杆菌有协同作用. 替卡西林钠 (4697-14-7)常和克拉维酸配伍制成新抗生素复合剂――泰门汀(Timentin),临床用于治疗严重感染.
欧盟法规
C&L通报海关参考信息
- 2905121000-正丙醇
2905130000-正丁醇
2912110000-甲醛
2912120000-乙醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2024197774-A1
优先权日:2021-04-16
标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles
发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO
权利人:UNIV TEXAS
摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.
专利号:US-8557979-B2
优先权日:2004-06-10
标题 :Carbapenem antibacterials with gram-negative activity and processes for their preparation
发明人:CHOI WOO-BAEG; KOWALIK EWA
权利人:CHOI WOO-BAEG; KOWALIK EWA; FOB SYNTHESIS INC
摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.
专利号:US-10933051-B2
优先权日:2017-06-09
标 题 :Carbapenem compounds and compositions for the treatment of bacterial infections
发明人:CHOI WOO-BAEG; TOMIOKA TAKASHI; JOO HYUNG-YEUL; TRUONG PHONG; MIN BRIAN
权利人:FOB SYNTHESIS INC
摘要:The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
专利号:US-9693999-B2
优先权日:2011-01-26
标题:Small molecule RNase inhibitors and methods of use
发明人:DUNMAN PAUL M; OLSON PATRICK D; CHILDERS WAYNE
权利人:UNIV ROCHESTER; UNIV NEBRASKA; Temple University—Of the Commonwealth System of Higher Education
摘要:Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
专利号:US-9937151-B2
优先权日:2010-06-18
标题 :Carbapenem antibacterials with gram-negative activity
发明人:CHOI WOO-BAEG; GRUSZECKA-KOWALIK EWA; JOO HYUNG-YEUL; LIU SHUANGPEI; MAO SHULI; LI YONGFENG; KIM DEOG-IL
权利人:FOB SYNTHESIS INC
摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
专利号:WO-9302193-A1
优先权日:1991-07-19
标题:cDNAS DERIVED FROM HEPATITIS C VIRUS
发明人:BARTOLOME NEBREDA FERNANDO JAV; CARRENO GARCIA VICENTE; CASTILLO AGUILAR INMACULADA; QUIROGA ESTEVEZ JUAN ANTONIO
权利人:BARTOLOME NEBREDA FERNANDO JAV; CARRENO GARCIA VICENTE; CASTILLO AGUILAR INMACULADA; QUIROGA ESTEVEZ JUAN ANTONIO
摘要:There is provided a series of sequences of cDNAS derived from hepatitis C virus (HCV). The comparison of the sequences of cDNAS obtained shows that they do not have any substantial homology with viruses A, B, and D of hepatitis. The comparison of these cDNAS with the disclosed sequences of HCV isolated in the United States and Japan shows a difference in this region of about 20 % with the one corresponding to that of the virus isolated in the United States and of about 10 % with the virus isolated in Japan. The sequences of cDNAS of HCV are useful for constructing probes and for the synthesis of polypeptides which may be used in immunoassays for diagnosis, control and follow-up in therapy, and developments of vaccines against hepatitis by C virus. The polypeptides coded by the sequences of cDNAS may also be used to produce and purify antibodies to antigens of HCV, as well as immunoassays to detect antigens of C virus. These antibodies may be used in the profilaxis of the infection. Background: hepatitis C is a disease which progresses, in half of the cases, by chronicity and is agressive since in 20 % of chronic cases a hepatic cirrhosis develops. One of the viruses responsible for this disease has been isolated in the United States from serum and liver of chimpanzee which had been previously inoculated with serum originating from a patient affected by hepatitis non-A, non-B (1). Subsequently, a related virus (2, 3) was isolated in Japan.